Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Unveiling Prognosis Cancer-Associated Thromboembolism Biomarkers and Their Related Polymorphisms: Exploring Their Involvement With Immune Circulating Cells and Therapeutic Reversibility

NCT06065592 is registered in ClinicalTrials.gov with Lebanese University as lead sponsor.

NCT NCT06065592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06065592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Unveiling Prognosis Cancer-Associated Thromboembolism Biomarkers and Their Related Polymorphisms: Exploring Their Involvement With Immune Circulating Cells and Therapeutic Reversibility
Lead sponsor
Lebanese University
Phase
Phase 1
Overall status
Unknown status
Start date
February 1, 2019
Completion date
December 31, 2024
Enrollment
500 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cancer, cardiovascular diseases, chemotherapy, colon cancer, hepatocellular carcinoma, immune system diseases, immunotherapy, inflammatory diseases, lung cancer, prostate cancer, solid tumor, thromboembolism